---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-22-000062"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2022-04-20T23:59:59+00:00"
generated_at: "2026-06-26T06:21:42.175278+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pfizer changes non-GAAP measure to include IPR&D costs; Q1 adj. income seen down ~$275M

## Summary
- Starting Q1 2022, acquired IPR&D costs (upfront/milestone payments, asset acquisitions) included in Adjusted income; prior periods recast.
- Expected Q1 2022 impact: Adjusted income reduced by ~$275M, Adjusted diluted EPS by ~$0.05.
- Acquired IPR&D expenses will appear as a separate income-statement line item going forward.
- FY guidance will include IPR&D costs for signed transactions through a defined date; excludes potential future deals.
- Recast GAAP-to-non-GAAP reconciliations for 2020 and 2021 to be posted on or before April 30, 2022.

## SEC filing metadata
- accession: 0000078003-22-000062
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2022-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800322000062/0000078003-22-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800322000062/pfe-20220420.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-22-000062
- JSON: https://secwatch.observer/filing/0000078003-22-000062.json
- Plain text: https://secwatch.observer/filing/0000078003-22-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.